Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Sleep Apnea Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Sleep Apnea Overview | 7 | 1 |
| Pipeline Products for Sleep Apnea Comparative Analysis | 8 | 1 |
| Sleep Apnea Therapeutics under Development by Companies | 9 | 1 |
| Sleep Apnea Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Sleep Apnea Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Sleep Apnea Products under Development by Companies | 14 | 1 |
| Sleep Apnea Products under Investigation by Universities/Institutes | 15 | 1 |
| Sleep Apnea Companies Involved in Therapeutics Development | 16 | 4 |
| Galleon Pharmaceuticals | 16 | 1 |
| RespireRx Pharmaceuticals Inc. | 17 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 18 | 1 |
| Vivus, Inc. | 19 | 1 |
| Sleep Apnea Therapeutics Assessment | 20 | 8 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Combination Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 1 |
| Assessment by Molecule Type | 27 | 1 |
| Drug Profiles | 28 | 18 |
| (phentermine + topiramate) ER Drug Profile | 28 | 7 |
| CX-1739 Drug Profile | 35 | 3 |
| dronabinol Drug Profile | 38 | 2 |
| GAL-475 Drug Profile | 40 | 1 |
| GAL-475 Backups Drug Profile | 41 | 1 |
| SKL-N05 Drug Profile | 42 | 3 |
| Small Molecule for Sleep Apnea Drug Profile | 45 | 1 |
| Sleep Apnea Dormant Projects | 46 | 1 |
| Sleep Apnea Discontinued Products | 47 | 1 |
| Sleep Apnea Product Development Milestones | 48 | 11 |
| Featured News &Press Releases | 48 | 1 |
| Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting | 48 | 1 |
| Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016 | 49 | 1 |
| Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA | 49 | 1 |
| May 14, 2015: VIVUS Announces Scientific Presentations | 50 | 1 |
| May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders | 51 | 1 |
| May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders | 52 | 1 |
| May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists | 52 | 1 |
| Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies | 53 | 1 |
| Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules | 54 | 1 |
| Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa | 55 | 1 |
| Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa | 55 | 1 |
| Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739 | 56 | 1 |
| Feb 02, 2011: Cortex s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients | 56 | 1 |
| Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |